Physician profile
John Delmas
NPI 1568476588
$2,150.25
in general payments reported to CMS, 2019-2025
21 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $67.19 · 2022: $139 · 2023: $236 · 2024: $634 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $305.02 | 2023-2025 | |
| Daiichi Sankyo INC. | $279.53 | 2024-2025 | Injectafer, Enhertu |
| Amgen INC. | $276.81 | 2019-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $256.97 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $185.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $156.25 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $140.94 | 2022-2025 | Ubrelvy, Synthroid, Vraylar |
| Astrazeneca Pharmaceuticals LP | $114.71 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $70.26 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $54.35 | 2022-2023 | Onzetra Xsail, Contrave |
| Amarin Pharma, INC. | $51.99 | 2019-2020 | |
| Radius Health, INC. | $49.64 | 2025 | Tymlos |
| Exact Sciences Corporation | $44.31 | 2023-2024 | Cologuard Collection Kit |
| Philips North America LLC | $32.66 | 2024-2025 | Mcot, (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $29.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.35 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.95 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $19.77 | 2024 | Gemtesa |
| Astellas Pharma US INC | $17.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Delmas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.